Vered Stearns

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
    Ann Surg Oncol 9:235-42. 2002
  2. ncbi request reprint Approach to menopausal symptoms in women with breast cancer
    Vered Stearns
    The Breast Cancer Program, University of Michigan Comprehensive Cancer Center, 6303 Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    Curr Treat Options Oncol 3:179-90. 2002
  3. pmc Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer
    N Lynn Henry
    University of MichiganComprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:936-42. 2012
  4. pmc Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St, Bldg 3A04, Ann Arbor, MI 48109 5419, USA
    Am J Psychiatry 165:1251-5. 2008
  5. pmc CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
    James M Rae
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    J Natl Cancer Inst 104:452-60. 2012
  6. ncbi request reprint Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
    Vered Stearns
    Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
    J Clin Oncol 23:6919-30. 2005
  7. pmc Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
    Aditya Bardia
    Breast Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building 1, Room 144, 1650 Orleans Street, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 131:907-14. 2012
  8. pmc A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5419, USA
    Cancer 116:4360-7. 2010
  9. pmc Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Breast Cancer Res Treat 117:571-5. 2009
  10. pmc Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
    Stephanie Gaillard
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
    Breast Cancer Res 13:205. 2011

Detail Information

Publications53

  1. ncbi request reprint Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
    Ann Surg Oncol 9:235-42. 2002
    ..Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy...
  2. ncbi request reprint Approach to menopausal symptoms in women with breast cancer
    Vered Stearns
    The Breast Cancer Program, University of Michigan Comprehensive Cancer Center, 6303 Cancer Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109 0942, USA
    Curr Treat Options Oncol 3:179-90. 2002
    ..Selective serotonin re-uptake inhibitors should be considered as a first-line nonhormonal pharmacologic therapy for women with menopausal symptoms...
  3. pmc Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer
    N Lynn Henry
    University of MichiganComprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:936-42. 2012
    ..Predictors of treatment discontinuation are not clearly defined. It is unknown whether patients with intolerable toxicity from one AI are able to tolerate another...
  4. pmc Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St, Bldg 3A04, Ann Arbor, MI 48109 5419, USA
    Am J Psychiatry 165:1251-5. 2008
  5. pmc CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
    James M Rae
    Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    J Natl Cancer Inst 104:452-60. 2012
    ..Previous studies have suggested that metabolic conversion of tamoxifen to endoxifen by cytochrome P450 2D6 (CYP2D6) is required for patient benefit from tamoxifen therapy...
  6. ncbi request reprint Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial
    Vered Stearns
    Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA
    J Clin Oncol 23:6919-30. 2005
    ..A secondary objective was to evaluate quality of life (QOL) parameters...
  7. pmc Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
    Aditya Bardia
    Breast Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building 1, Room 144, 1650 Orleans Street, Baltimore, MD 21231, USA
    Breast Cancer Res Treat 131:907-14. 2012
    ..Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD...
  8. pmc A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5419, USA
    Cancer 116:4360-7. 2010
    ..Tendon sheath fluid and tenosynovial changes have been demonstrated by imaging symptomatic patients who were treated with AIs. The authors hypothesized that these abnormalities are correlated with AIMSS...
  9. pmc Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Breast Cancer Res Treat 117:571-5. 2009
    ..062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy...
  10. pmc Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management
    Stephanie Gaillard
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 144, Baltimore, MD 21231, USA
    Breast Cancer Res 13:205. 2011
    ..Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes...
  11. ncbi request reprint A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity
    Vered Stearns
    Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA
    Clin Cancer Res 10:8332-40. 2004
    ..We chose tamoxifen to establish proof of principal with a known effective agent...
  12. pmc Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors
    Yong Soon Chun
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Breast Cancer Res Treat 135:201-8. 2012
    ..Unless there are fundamental species differences in PLD metabolism in rodents and humans, this finding seriously limits the consideration of i.duc PLD use in the clinic for treatment or prevention of breast cancer...
  13. doi request reprint CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance
    Michaela J Higgins
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, CRBI, Room 145, Baltimore, MD 21231, USA
    Curr Oncol Rep 12:7-15. 2010
    ..This review summarizes the literature to date with a focus on clinically relevant recent studies that examined the association between CYP2D6 polymorphisms and tamoxifen-associated outcomes...
  14. pmc Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Med Inn Bldg C450, Ann Arbor, MI 48109 5843, USA
    Breast Cancer Res Treat 138:807-16. 2013
    ..An inherited variant potentially affecting estrogen signaling may be associated with exemestane-associated toxicity, which could partially account for intra-patient differences in AI tolerability. Validation of this finding is required...
  15. ncbi request reprint Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management
    N Lynn Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan 48109 5419, USA
    Oncology (Williston Park) 22:1401-8. 2008
    ..Increased knowledge about the etiology and management of this clinically important toxicity could potentially improve patient adherence to AI therapy, thereby leading to a reduction in breast cancer recurrence and death...
  16. ncbi request reprint Management of hot flashes in breast cancer survivors and men with prostate cancer
    Vered Stearns
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Room 1M53, Baltimore, MD 21231 1000, USA
    Curr Oncol Rep 6:285-90. 2004
    ..However, such hormonal therapies as depomedroxyprogesterone acetate can be prescribed for an informed individual who experiences bothersome symptoms despite nonhormonal treatments...
  17. ncbi request reprint Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
    Vered Stearns
    The Breast Cancer Program, Department of Medicine, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Natl Cancer Inst 95:1758-64. 2003
    ..In a prospective clinical trial, we tested the effects of coadministration of tamoxifen and the SSRI paroxetine, an inhibitor of CYP2D6, on tamoxifen metabolism...
  18. pmc Preclinical and clinical evaluation of intraductally administered agents in early breast cancer
    Vered Stearns
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Sci Transl Med 3:106ra108. 2011
    ..If successful, administration of agents directly into the ductal system may allow for "breast-sparing mastectomy" in select women...
  19. ncbi request reprint Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
    Vered Stearns
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Nat Rev Cancer 6:886-93. 2006
    ..Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions...
  20. pmc Biomarker modulation following short-term vorinostat in women with newly diagnosed primary breast cancer
    Vered Stearns
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Cancer Res 19:4008-16. 2013
    ..We evaluated biomarker modulation in breast cancer tissues obtained from women with newly diagnosed invasive disease who received vorinostat and those who did not...
  21. ncbi request reprint More choices, more questions: weighing the options for treating hot flashes
    Vered Stearns
    Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Support Oncol 4:323-5. 2006
  22. ncbi request reprint A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D C, USA
    Clin Cancer Res 10:7583-91. 2004
    ..We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the "window" between diagnostic and definitive surgery...
  23. ncbi request reprint Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial
    Vered Stearns
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    JAMA 289:2827-34. 2003
    ..Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective...
  24. pmc Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Clin Oncol 27:5911-8. 2009
    ..We tested the hypothesis that cyclophosphamide (CY) and doxorubicin (DOX) can enhance vaccine-induced immunity in patients with breast cancer...
  25. ncbi request reprint Epigenetic regulation as a new target for breast cancer therapy
    Vered Stearns
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Invest 25:659-65. 2007
  26. pmc Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
    N Lynn Henry
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0942, USA
    Breast Cancer Res Treat 111:365-72. 2008
    ..AIs are commonly associated with musculoskeletal symptoms. The primary objective of this study was to describe the musculoskeletal symptoms that developed in the first 100 subjects enrolled who had at least 6 months follow-up...
  27. ncbi request reprint A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer
    Vered Stearns
    Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA
    Clin Cancer Res 9:124-33. 2003
    ....
  28. ncbi request reprint Hot flushes
    Vered Stearns
    Breast Oncology Program, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Georgetown, USA
    Lancet 360:1851-61. 2002
    ..Moreover, the efficacy of these drugs provides new insight into the pathophysiology of hot flushes. In this critical review, we assess knowledge of the epidemiology, pathophysiology, and treatment of hot flushes...
  29. ncbi request reprint Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Antonio C Wolff
    J Clin Oncol 24:2392-4; author reply 2394-5. 2006
  30. ncbi request reprint Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
    ..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
  31. ncbi request reprint Centrally active nonhormonal hot flash therapies
    Charles L Loprinzi
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Am J Med 118:118-23. 2005
    ..The most efficacious and clinically appropriate agents for use are newer antidepressants and gabapentin. Continued evaluation of the efficacy and toxicity of these agents is ongoing...
  32. pmc CYP2D6 genotype and tamoxifen response
    James M Rae
    Breast Cancer Res 7:E6. 2005
  33. ncbi request reprint CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
    Yan Jin
    Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    J Natl Cancer Inst 97:30-9. 2005
    ....
  34. ncbi request reprint Cooling off hot flashes
    Vered Stearns
    J Clin Oncol 20:1436-8. 2002
  35. ncbi request reprint Can hypnosis reduce hot flashes in breast cancer survivors? A literature review
    Gary Elkins
    Scott and White Hospital and Clinic, Temple, TX 76508, USA
    Am J Clin Hypn 47:29-42. 2004
    ..However this intervention has not been adequately studied. We discuss an NIH-funded randomized clinical trial of hypnosis for hot flashes in breast cancer survivors that is presently being conducted...
  36. ncbi request reprint New therapeutic approaches for hot flashes in women
    Vered Stearns
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231 1000, USA
    J Support Oncol 1:11-21; discussion 14-5, 19-21. 2003
    ..We will focus on nonhormonal treatments that have been studied in prospective randomized clinical trials, and will present an algorithm for the treatment of symptomatic patients...
  37. ncbi request reprint Déjà vu for breast cancer two?
    Vered Stearns
    J Natl Cancer Inst 96:497-9. 2004
  38. ncbi request reprint Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond
    Ting Bao
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231 1000, USA
    Am J Ther 13:337-48. 2006
    ....
  39. pmc Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors
    Gary Elkins
    Department of Psychology and Neuroscience, Baylor University, Waco, TX 76798, USA
    J Clin Oncol 26:5022-6. 2008
    ..A well-tolerated and effective mind-body treatment for hot flashes would be of great value. On the basis of previous case studies, this study was developed to evaluate the effect of a hypnosis intervention for hot flashes...
  40. pmc A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
    Daniel F Hayes
    J Natl Cancer Inst 100:610-3. 2008
  41. ncbi request reprint Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment
    Silvana Borges
    Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, 46202, USA
    Clin Pharmacol Ther 80:61-74. 2006
    ..We conducted a prospective trial in 158 patients with breast cancer who were taking tamoxifen to further understand the effect of CYP2D6 genotype and concomitant medications on endoxifen plasma concentrations...
  42. ncbi request reprint Role of CYP2D6 testing in selection of endocrine therapy for breast cancer
    Justin Stebbing
    Pharmacogenomics 8:1-3. 2007
  43. ncbi request reprint Clinical update: new treatments for hot flushes
    Vered Stearns
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Lancet 369:2062-4. 2007
  44. ncbi request reprint Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT
    Heather A Jacene
    Division of Nuclear Medicine, The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Clin Nucl Med 31:379-81. 2006
    ..This case highlights the importance of clinical history and laboratory correlation for the proper interpretation of FDG PET scans...
  45. ncbi request reprint Extended adjuvant therapy for breast cancer--how much is enough?
    Tatiana M Prowell
    J Natl Cancer Inst 99:1825-7. 2007
  46. ncbi request reprint Lipophilic statins merit additional study for breast cancer chemoprevention
    Tatiana M Prowell
    J Clin Oncol 24:2128-9; author reply 2129. 2006
  47. ncbi request reprint Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications
    Michael A Jacobs
    The Russell H Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Technol Cancer Res Treat 3:543-50. 2004
    ..A combination of MR, MRSI, and 23Na sodium MR parameters may be examined in a single MR imaging examination, potentially resulting in improved specificity for radiologic evaluation of malignancy...
  48. ncbi request reprint Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI
    Ronald Ouwerkerk
    Division of MR Research, Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21287 0845, USA
    Breast Cancer Res Treat 106:151-60. 2007
    ....
  49. ncbi request reprint Chemotherapeutic Strategies for advanced breast cancer
    Susanne Briest
    University of Leipzig Department of Gynecology and Obstetrics Leipzig, Germany
    Oncology (Williston Park) 21:1325-35; discussion 1338, 1340. 2007
    ..In this review, we will provide an update on commonly used chemotherapy-based regimens for the treatment of metastatic breast cancer, with a focus on tailoring therapy to different subtypes of the disease...
  50. ncbi request reprint Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors
    Gary Elkins
    Mind Body Cancer Research Program, Scott and White Memorial Hospital, Temple, TX, USA
    Psychooncology 16:487-92. 2007
    ..A randomized, controlled clinical trial is planned to more definitively elucidate the efficacy and applicability of hypnosis for reducing hot flashes...
  51. ncbi request reprint A phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin
    Leisha A Emens
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231 2410, USA
    Hum Gene Ther 15:313-37. 2004
  52. ncbi request reprint Adjuvant aromatase inhibitors and emerging quality-of-life considerations
    Susanne Briest
    Expert Rev Anticancer Ther 8:1-4. 2008
  53. ncbi request reprint Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies
    Heather A Jacene
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland, USA
    J Nucl Med 47:950-6. 2006
    ..The purpose of this study was to evaluate the effects of pegfilgrastim, a long-acting granulocyte colony-stimulating factor, on the normal biodistribution of (18)F-FDG in an animal model and in humans...